12/26
09:24 am
adpt
Adaptive Biotechnologies: 2026 Is The Durability Test, Not The Hype Cycle [Seeking Alpha]
Low
Report
Adaptive Biotechnologies: 2026 Is The Durability Test, Not The Hype Cycle [Seeking Alpha]
12/15
08:10 am
adpt
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer [Yahoo! Finance]
Low
Report
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer [Yahoo! Finance]
12/15
08:00 am
adpt
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
Low
Report
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
12/9
05:53 pm
adpt
Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease [Yahoo! Finance]
Medium
Report
Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease [Yahoo! Finance]
12/9
05:07 pm
adpt
Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease
Medium
Report
Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease
12/6
08:30 am
adpt
Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting
Low
Report
Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting
12/3
10:26 pm
adpt
Assessing Adaptive Biotechnologies (ADPT) Valuation After a 179% One-Year Rebound and Recent Pullback [Yahoo! Finance]
Low
Report
Assessing Adaptive Biotechnologies (ADPT) Valuation After a 179% One-Year Rebound and Recent Pullback [Yahoo! Finance]
12/1
06:03 pm
adpt
Adaptive Biotechnologies (NASDAQ:ADPT) was given a new $21.00 price target on by analysts at Morgan Stanley.
Low
Report
Adaptive Biotechnologies (NASDAQ:ADPT) was given a new $21.00 price target on by analysts at Morgan Stanley.
11/24
07:30 am
adpt
Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting
Medium
Report
Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting
11/22
10:16 am
adpt
Adaptive Biotechnologies (ADPT) Hits 3-Year High. Here's Why [Yahoo! Finance]
Medium
Report
Adaptive Biotechnologies (ADPT) Hits 3-Year High. Here's Why [Yahoo! Finance]
11/17
09:22 am
adpt
Continued Momentum Lifted Adaptive Biotechnologies Corporation (ADPT) in Q3 [Yahoo! Finance]
Medium
Report
Continued Momentum Lifted Adaptive Biotechnologies Corporation (ADPT) in Q3 [Yahoo! Finance]
11/11
11:42 am
adpt
Adaptive Biotechnologies (NASDAQ:ADPT) had its price target raised by analysts at Morgan Stanley from $11.00 to $16.00. They now have an "equal weight" rating on the stock.
Low
Report
Adaptive Biotechnologies (NASDAQ:ADPT) had its price target raised by analysts at Morgan Stanley from $11.00 to $16.00. They now have an "equal weight" rating on the stock.
11/7
07:07 pm
adpt
Adaptive Biotechnologies (ADPT) Surges to First Profit and Lifts Guidance—Has the Investment Case Evolved? [Yahoo! Finance]
Low
Report
Adaptive Biotechnologies (ADPT) Surges to First Profit and Lifts Guidance—Has the Investment Case Evolved? [Yahoo! Finance]
11/7
08:07 am
adpt
Adaptive Biotechnologies (NASDAQ:ADPT) had its price target raised by analysts at BTIG Research from $19.00 to $21.00. They now have a "buy" rating on the stock.
Low
Report
Adaptive Biotechnologies (NASDAQ:ADPT) had its price target raised by analysts at BTIG Research from $19.00 to $21.00. They now have a "buy" rating on the stock.
11/6
04:27 pm
adpt
Adaptive Biotechnologies (NASDAQ:ADPT) had its price target raised by analysts at JPMorgan Chase & Co. from $17.00 to $20.00. They now have an "overweight" rating on the stock.
Medium
Report
Adaptive Biotechnologies (NASDAQ:ADPT) had its price target raised by analysts at JPMorgan Chase & Co. from $17.00 to $20.00. They now have an "overweight" rating on the stock.
11/6
04:05 pm
adpt
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
Medium
Report
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
11/5
05:41 pm
adpt
Adaptive Biotechnologies: Q3 Earnings Snapshot [Yahoo! Finance]
Low
Report
Adaptive Biotechnologies: Q3 Earnings Snapshot [Yahoo! Finance]
11/5
04:05 pm
adpt
Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results
High
Report
Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results
10/22
08:34 am
adpt
Adaptive Biotechnologies (NASDAQ:ADPT) had its price target raised by analysts at BTIG Research from $14.00 to $19.00. They now have a "buy" rating on the stock.
Medium
Report
Adaptive Biotechnologies (NASDAQ:ADPT) had its price target raised by analysts at BTIG Research from $14.00 to $19.00. They now have a "buy" rating on the stock.
10/17
08:10 pm
adpt
Can This Red-Hot Biotech Stock Live Up to Wall Street's Expectations? [Yahoo! Finance]
Medium
Report
Can This Red-Hot Biotech Stock Live Up to Wall Street's Expectations? [Yahoo! Finance]
10/15
04:05 pm
adpt
Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025
Low
Report
Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025
10/15
08:50 am
adpt
Adaptive Biotechnologies (NASDAQ:ADPT) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Medium
Report
Adaptive Biotechnologies (NASDAQ:ADPT) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
10/13
09:19 am
adpt
Adaptive Biotechnologies (NASDAQ:ADPT) had its price target raised by analysts at JPMorgan Chase & Co. from $14.00 to $17.00. They now have an "overweight" rating on the stock.
Low
Report
Adaptive Biotechnologies (NASDAQ:ADPT) had its price target raised by analysts at JPMorgan Chase & Co. from $14.00 to $17.00. They now have an "overweight" rating on the stock.
10/6
01:32 pm
adpt
Adaptive Biotechnologies: Current Moat Is Strong, But Value Rides On Long-Term Innovation (Rating Upgrade) [Seeking Alpha]
Low
Report
Adaptive Biotechnologies: Current Moat Is Strong, But Value Rides On Long-Term Innovation (Rating Upgrade) [Seeking Alpha]
10/3
02:37 pm
adpt
Adaptive Biotechnologies (NASDAQ:ADPT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Adaptive Biotechnologies (NASDAQ:ADPT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.